Document Detail


Evaluation of intravaginal misoprostol for medical management of pregnancies less than 20 weeks of gestation with absent cardiac activity.
MedLine Citation:
PMID:  20598047     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To assess the efficacy and side-effects of misoprostol (800 microg used intravaginally) for terminating non-viable pregnancies up to 20 weeks of gestation.
METHODS: Sixty five patients with non-viable pregnancies up to 20 weeks of gestation were given 800 microg misoprostol intravaginally on day 1. A second dose of 800 microg was repeated after 24 h if complete abortion was not attained with one dose. Primary outcome measure was success (defined as complete abortion in 48 h without surgical intervention). Duration and amount of blood loss, fall in hemoglobin, and other side-effects (pain, vomiting, diarrhea, fever and chills) were studied as secondary outcome measures.
RESULTS: 73.8% of our patients had a gestational age <or=12 weeks (group A) and 26.2% had a gestational age between 12 and 20 weeks (group B). Success rate after one dose was 66.1% and rose to 84.6% after the second dose. Success rate was higher with increasing gestation (81.2% in group A vs 94.1% in group B). Mean induction abortion interval was 18.8 +/- 11.6 h in group A and 10.8 +/- 6.2 h in group B. Mean duration of bleeding was 9.4 +/- 2.3 days. Average blood loss was 134.9 +/- 113.2 mL. No patient required blood transfusion. Mean fall in hemoglobin was 0.56 +/- 0.48 g/dL. Most patients had mild pain. Only 6.2% had severe pain requiring injectable narcotic analgesics. Other side-effects were minimal. Patients who failed to abort completely with misoprostol underwent surgical evacuation.
CONCLUSION: 800 microg vaginal misoprostol is an effective regimen for termination of non-viable pregnancies <20 weeks of gestation. It has minimal side-effects and avoids surgical intervention.
Authors:
Puneet K Kochhar; Gauri Gandhi; Swaraj Batra; Vijay Zutshi
Related Documents :
16529667 - A randomized trial comparing oral misoprostol with intra-amniotic prostaglandin f2alpha...
2216207 - Enhanced anaphylatoxin and terminal c5b-9 complement complex formation in patients with...
14989807 - One- and 2-day mifepristone-misoprostol intervals are both effective in medical termina...
12424757 - The influence of prenatal screening and termination of pregnancy on perinatal mortality...
1987957 - Blood velocity waveforms in the fetal aorta and umbilical artery as predictors of fetal...
23466397 - A weight-gain-for-gestational-age z score chart for the assessment of maternal weight g...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The journal of obstetrics and gynaecology research     Volume:  36     ISSN:  1447-0756     ISO Abbreviation:  J. Obstet. Gynaecol. Res.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-07-05     Completed Date:  2010-10-08     Revised Date:  2012-01-19    
Medline Journal Info:
Nlm Unique ID:  9612761     Medline TA:  J Obstet Gynaecol Res     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  626-33     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Lok Nayak Hospital, New Delhi, India. sonia.k20@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortifacient Agents, Nonsteroidal / administration & dosage,  therapeutic use
Abortion, Induced / methods*
Administration, Intravaginal
Adult
Age Factors
Female
Humans
Misoprostol / administration & dosage*,  therapeutic use
Pregnancy
Prospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 59122-46-2/Misoprostol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Utilization of therapeutic intervention to prevent mother to child transmission of HIV in a teaching...
Next Document:  Ultrasonographic evaluation of endometrial changes using computer assisted image analysis.